| Not Yet Recruiting | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metast NCT07449481 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu NCT06824363 | University of California, Irvine | EARLY_Phase 1 |
| Not Yet Recruiting | A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT07136142 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors NCT06771921 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT06735144 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as NCT06391775 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 | Ankyra Therapeutics, Inc | Phase 1 |
| Active Not Recruiting | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors NCT06057038 | Genmab | Phase 1 |
| Terminated | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors NCT05859464 | Zai Lab (Hong Kong), Ltd. | Phase 1 |
| Completed | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors NCT05727839 | Immorna Biotherapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With NCT05629689 | GE Healthcare | Phase 1 |
| Recruiting | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Pat NCT05468359 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors NCT05539157 | Immorna Biotherapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Ly NCT05141474 | Vall d'Hebron Institute of Oncology | EARLY_Phase 1 |
| Active Not Recruiting | A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in NCT04632108 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors NCT04571892 | Shanghai East Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristic NCT04116541 | Centre Leon Berard | Phase 2 |
| Recruiting | CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) NCT04151342 | University Health Network, Toronto | — |
| Completed | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT NCT04168528 | Universitair Ziekenhuis Brussel | Phase 1 / Phase 2 |
| Recruiting | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors NCT04145622 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Active Not Recruiting | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 | Genmab | Phase 1 / Phase 2 |
| Unknown | Targeted T-cell Therapy in Solid Tumors NCT04076137 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | EARLY_Phase 1 |
| Completed | Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services NCT03905720 | University of California, San Francisco | N/A |
| Completed | A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies NCT03834662 | Bristol-Myers Squibb | Phase 1 |
| Active Not Recruiting | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence NCT03694249 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. NCT03553108 | AstraZeneca | Phase 1 |
| Completed | Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor NCT03551795 | Xiaoyan Zhang | Phase 1 / Phase 2 |
| Completed | A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 NCT03192345 | Sanofi | Phase 1 |
| Completed | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours NCT03009214 | amcure GmbH | Phase 1 |
| Completed | Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generati NCT02844400 | UNC Lineberger Comprehensive Cancer Center | — |
| Terminated | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) NCT02801097 | EpicentRx, Inc. | Phase 1 |
| Completed | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination W NCT02754141 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab NCT02518958 | EpicentRx, Inc. | Phase 1 |
| Completed | Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers NCT02252211 | Ludwig Institute for Cancer Research | Phase 1 |
| Terminated | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 NCT02096341 | EpicentRx, Inc. | Phase 1 |
| Unknown | EXtendedAnalysis for Cancer Treatment NCT02999750 | Medical University of Vienna | N/A |
| Terminated | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain NCT01846429 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin NCT01606748 | Eli Lilly and Company | Phase 2 |
| Completed | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors NCT01670175 | University of California, San Francisco | Phase 1 |
| Completed | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors NCT01515306 | Eli Lilly and Company | Phase 2 |
| Completed | A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors NCT01567163 | Eli Lilly and Company | Phase 2 |
| Terminated | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors NCT01632696 | Peregrine Pharmaceuticals | EARLY_Phase 1 |
| Completed | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies NCT01457118 | Nektar Therapeutics | Phase 2 |
| Completed | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects NCT01359982 | EpicentRx, Inc. | Phase 1 |
| Terminated | Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients NCT01309490 | Jewish General Hospital | Phase 1 / Phase 2 |
| Completed | ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan NCT00836888 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread NCT01648764 | Eli Lilly and Company | Phase 1 |
| Completed | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma NCT00725634 | AVEO Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer NCT00452413 | Eli Lilly and Company | Phase 1 / Phase 2 |